Glaukos Corporation Announces First Quarter 2019 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2019. Key highlights include: Achieved 35% net sales growth to $54.0 million in the first quarter of 2019, compared to $40.1 millio

Full Story →